Quantcast

Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com

July 14, 2014

ReportsnReports.com adds “EpiCast Report Acute Coronary Syndrome (ACS) – Epidemiology Forecast to 2022” to its store. The majority of the cases occurred in men (58.15%) and in those ages 65 years (69.34%).

Dallas, TX (PRWEB) July 14, 2014

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person’s symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

Complete Report Available at http://www.reportsnreports.com/reports/292055-epicast-report-acute-coronary-syndrome-acs-epidemiology-forecast-to-2023.html .

This report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2013 to 2023 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The epidemiological patient forecast includes:

  •     Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA
  •     ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA
  •     ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA
  •     Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2013 to 2023 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK)

In the 7MM, the hospitalized incident cases of ACS will increase from 1.29 million cases in 2013 to 1.47 million cases in 2023 at the rate of 1.40% per year. The US constitutes around 40% of the total hospitalized incident ACS cases in the 7MM and will be the market with the highest number of cases during the forecast period. The majority of the cases occurred in men (58.15%) and in those ages ≥65 years (69.34%). For the 7MM, about 33% of the ACS cases were STEMI, 44% were NSTEMI, and 23% were UA. The proportions varied depending on the market.

Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=292055

Reasons to buy

  •     Develop business strategies by understanding the trends shaping and driving the global ACS market.
  •     Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
  •     Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for ACS therapeutics in each of the markets covered.
  •     Identify the number of ACS cases survived to key time periods.

1 Table of Contents

2 Introduction

2.1 Catalyst

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global Trends – MI

3.4 Global Trends – UA

3.5 Forecast Methodology

3.6 Epidemiological Forecast for ACS (2013-2023) – Hospitalized Incident Cases

3.7 Epidemiological Forecast for MI (2013-2023) – Prevalent Cases

3.8 Discussion

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.3 About GlobalData

4.4 About EpiCast

4.5 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for CHD and ACS

Table 2: Germany, MI Incidence and Re-Infarction Rates (Cases per 100,000 Population), 1985-1987 and 2001-2003

Table 3: Spain, MI Incidence Rate (Cases per 100,000 Population) and Incidence Trends, 2000 and 2013

Table 4: England and Scotland, Temporal Trends in the MI Incidence (Cases per 100,000 Population), 2002-2010

Table 5: 7MM, Summary of STEMI and NSTEMI In-Hospital and One-Year Case-Fatality Rates

Table 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants

Table 7: 7MM, Sources of MI and UA Incidence Data

Table 8: 7MM, Sources of Diagnosed Prevalence Data for MI

Table 9: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Hospitalized Cases of MI

Table 10: 7MM, Hospitalized Incident Cases of ACS, Ages =25 Years, Both Sexes, N (Col %), Selected Years, 2013-2023

Table 11: 7MM, Age-Specific Hospitalized Incident Cases of ACS, Both Sexes, N (Row %). 2013

Table 12: 7MM, Sex-Specific Hospitalized Incident Cases of ACS, Ages =25 Years, N (Row %), 2013

Table 13: 7MM, Hospitalized Incident Cases of ACS Segmented by STEMI, NSTEMI, and UA (N, Row %), Ages =25 Years, Both Sexes, 2013

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:

ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

For the original version on PRWeb visit: http://www.prweb.com/releases/acute-coronary-syndrome/epidemiology-forecast2023/prweb12015229.htm


Source: prweb



comments powered by Disqus